Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apimeds Pharmaceuticals UsAPUS -2.06%13 Cash-to-Debt is 0.02 as of Jun. 2026, which is 94% below its 10-year median of 0.36. GuruFocus rates APUS with a GF Score™ of 13/100. The stock has 3 warning signs investors should review. Among 979 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 96.12% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Apimeds Pharmaceuticals Us's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Apimeds Pharmaceuticals Uscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Apimeds Pharmaceuticals Us's Cash-to-Debt or its related term are showing as below:
APUS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.36 Max: 17.47
Current: 0.02
During the past 5 years, Apimeds Pharmaceuticals Us's highest Cash to Debt Ratio was 17.47. The lowest was 0.01. And the median was 0.36.
APUS's Cash-to-Debt is ranked worse than 96.12% of 979
companies
in the Drug Manufacturers industry
Industry Median: 0.97
vs APUS: 0.02
Apimeds Pharmaceuticals Us (AMEX:APUS) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Apimeds Pharmaceuticals Us Cash-to-Debt Related Terms
Apimeds Pharmaceuticals Us Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apimeds Pharmaceuticals Us Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Apimeds Pharmaceuticals Us's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apimeds Pharmaceuticals Us (APUS) has a Cash-to-Debt of 0.02 as of Jun. 2026. This is 94% below median its historical median of 0.36. Over the past decade, Apimeds Pharmaceuticals Us' Cash-to-Debt has ranged from 0.01 to 17.47. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #941 out of 979 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Apimeds Pharmaceuticals Us' Cash-to-Debt too high?
Apimeds Pharmaceuticals Us' current Cash-to-Debt of 0.02 is 94% below median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 17.47. The Drug Manufacturers industry median Cash-to-Debt is 0.97. Apimeds Pharmaceuticals Us' value of 0.02 is 97.9% below this industry median. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #941 out of 979 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Cash-to-Debt compare to GELS and BTAI?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #941 out of 979 companies for Cash-to-Debt. This places Apimeds Pharmaceuticals Us in the lower half of its industry. The industry median Cash-to-Debt is 0.97. Apimeds Pharmaceuticals Us' value of 0.02 is 97.9% below this benchmark. Historically, Apimeds Pharmaceuticals Us' own Cash-to-Debt has ranged from 0.01 to 17.47 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 0.97, Apimeds Pharmaceuticals Us has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apimeds Pharmaceuticals Us's current Cash-to-Debt of 0.02 is 97.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current Cash-to-Debt is 0.02, which is 94% below median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Cash-to-Debt of 0.02. The current Cash-to-Debt is 0.02, which is 94% below median its 10-year median of 0.36 and 97.9% below the Drug Manufacturers industry median of 0.97. Apimeds Pharmaceuticals Us' overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Cash-to-Debt is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
13GF Score
Get the complete analysis for APUS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APUS has been successfully added to your 
